Search
Sign Up
Home
Team
Pipeline
Back
Sr89/Metastron
QBM-001
Uttroside-B
MAN-01
Investors
Back
Presentations
Stock Info
Filings
Media
News
Back
News 2025
News 2024
News 2023
News 2022
News 2021
News 2020
News 2019
News 2018
News 2017
News 2016
Contact
Video & Social Media
Watch us in interviews. Follow us.
2020 News
List of articles in category 2020 News
Title
Created Date
Q BioMed Updates Shareholders at Year End
Dec 29, 2020
Q BioMed Technology Partner Mannin Research Inc. Announced as Member of Canadian National COVID-19 Consortium
Dec 21, 2020
Q BioMed's Strontium89 Advertisement "Unfinished Business" Selected for Prestigious Ads of the World's Best Creative Campaigns
Nov 20, 2020
Q BioMed’s Uttroside-B Receives U.S. Patent in Treatment of Liver Cancer
Nov 16, 2020
Q BioMed Announces Strontium89 Initial Uptake and Momentum in US and Europe
Sep 15, 2020
Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
Aug 26, 2020
Q BioMed Announces Strontium89 will be available as of September 2020 through Named Patient Program for Bone Metastases Pain Palliation in EU and Rest of World
Aug 11, 2020
Q BioMed To Scale Up Production Of Uttroside-B, A Novel Chemotherapeutic For Liver Cancer, In Preparation For IND Filing
Jul 22, 2020
Q BioMed Announces Global Distribution Partnership with Caligor Coghlan Pharma Services for its Non-Opioid Cancer Palliation Drug
Jul 08, 2020
Q BioMed Updates Shareholders
Jun 30, 2020
Q BioMed Launches New Website Strontium89.com and Digital Marketing Campaign for Strontium89 (Strontium Chloride Sr-89 Injection, USP) Non-Opioid Treatment for Metastatic Bone Pain
May 15, 2020
Denis Corin, CEO, of Q BioMed Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
Apr 30, 2020
Q BioMed Inc. Discusses The Commercialization of Its FDA Approved Metastatic Bone Pain Drug with The Stock Day Podcast
Apr 27, 2020
Q BioMed Initiates Rapid Development of Novel COVID-19 Therapeutics
Apr 22, 2020
Q BioMed Enters into a Financial Restructuring of Approximately $7,800,000 Consisting of $4,000,000 New Cash and a minimum of $3,800,000 of Debt Conversion
Apr 07, 2020
Q BioMed Adds to Leadership Team with Global Head of Regulatory Affairs
Mar 31, 2020
Q BioMed Expands Leadership Team with Chief Commercial Officer
Mar 30, 2020
Q BioMed Treats its First Patient in Commercial Setting Following Product Launch
Mar 12, 2020
Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain
Feb 13, 2020
Q BioMed Partner Mannin Research Developing Potential Treatment for Patients Infected with Coronavirus and other Infectious Diseases
Feb 04, 2020
Q BioMed Provides a Shareholder Update Ahead of the Commercial Launch of its First Drug
Jan 07, 2020